Rubeosis Anti-VEGF (RAVE) Trial for Ischemic Central Retinal Vein Occlusion
Part of paid clinical trials in Houston, Texas.
- Sponsor
- Greater Houston Retina Research
- Study ID
- NCT00406471
- Phase
- PHASE1
- Status
- Completed
Conditions
- Ischemic Central Retinal Vein Occlusion
Eligibility Criteria
- Sex
- ALL
- Age
- 19 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Ranibizumab (Lucentis) — DRUG500 microgram intravitreal injection for 8 months or 300 microgram intravitreal injection for 8 months
Study Details
The RAVE (Rubeosis Anit-VEgf) trial, utilizes monthly intravitreal Ranibizumab (Lucentis) injections for 9 months to see if total VEGF blockade will prevent neovascular glaucoma and eliminate the need for panretinal photocoagulation in patients with ischemic central retinal vein occlusion.
Key Dates
- First listed
- Dec 4, 2006
- Start date
- May 31, 2005
- Status verified
- Mar 2013
- Primary completion
- Jan 31, 2011
- Completion
- Jan 31, 2011
Study Design
- Enrollment
- 20 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: 1500 micrograms of ranibizumab
- Active Comparator: 2300 microgram ranibizumab
Primary Outcome Measure
Preservation of 5Ve isopter Goldmann visual field versus baseline at 1 year [ Time Frame: 12 and 24 months ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Vitreoretinal Consultants | Houston | Texas | 77030 | - |
Find similar trials in Houston, TX
By research site